Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesBariatric & Obesity ManagementUnitedHealthcare Bariatric Surgery Coverage Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedUnitedHealthcarePolicy CS007NE.V

    Bariatric Surgery (for Nebraska Only)

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy CS007NE.V alerts

    Get alerted when Policy CS007NE.V changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Nebraska-specific UnitedHealthcare medical policy governing coverage criteria and coding for bariatric surgery and related procedures for Community Plan members in Nebraska.

    Policy Summary
    PayerUnitedHealthcare
    PolicyBariatric Surgery (for Nebraska Only)
    Policy CodePolicy CS007NE.V
    Change TypeMaterial revisions to coverage criteria and updates to unproven/not medically necessary listCPT code added
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionInclude thorough multidisciplinary documentation and evidence of prior conservative therapies when requesting prior authorization; add CPT 43889 where applicable.
    SourceLink
    POLICY UPDATE CHANGES

    Revised coverage criteria for a planned two-stage procedure; replaced criterion requiring the individual has been compliant with nutrition and exercise with individual has been adherent to nutrition and exercise.

    Added several procedures to the list of unproven and not medically necessary procedures, including silastic ring vertical gastric bypass and transoral endoscopic surgery including transoral outlet reduction (TORe).

    Removed 'stomach aspiration therapy' from the list of unproven and not medically necessary procedures.

    Added CPT code 43889 to the list of applicable codes.

    Added language clarifying that medical records documentation may be required to assess whether the member meets clinical criteria but does not guarantee coverage, and specifying types of documentation that should be included.

    Nebraska-onlypolicy applicability
    ≥50initial BMI threshold
    ≤2 yearsplanned two-stage interval
    Center of ExcellenceCenter requirement
    1CPT codes added

    Coverage Criteria and Policy Positions

    Planned two-stage procedure

    Covered when ALL of the following are met:

    Planned two-stage procedure criteria: Initial BMI of ≥ 50 kg/m2 prior to first-stage bariatric procedure; AND second stage occurs within 2 years following the primary bariatric surgery procedure; AND individual has been adherent to nutrition and exercise; AND individual meets medical necessity criteria listed above at the time of the second-stage proceduresee node text

    From Non-State-Specific Criteria

    Revisional Bariatric Surgery - when proven medically necessary

    Revisional bariatric surgery is covered when due to a technical failure or major complication from the initial procedure, including but not limited to:

    Examples of indications for covered revisional surgery: Bowel perforation (including adjustable gastric band erosion); Adjustable gastric band migration (slippage) that cannot be corrected with manipulation or adjustment (records must demonstrate manipulation/adjustment attempted); Leak; Obstruction (confirmed by imaging studies); Staple-line failure; Mechanical adjustable gastric band failure; Uncontrollable reflux related to sleeve gastrectomy when all of the following are met: maximum nonpharmacological medical management failure (e.g., positional, dietary modification, behavioral changes); AND maximum pharmacological medical management failure (e.g., at least 1 month of double-dose PPI, H2 blocker, and/or sucralfate); AND severe esophagitis (grade C or D) confirmed by endoscopy despite maximum medical management; AND Removal of an adjustable gastric band and all related components when not resulting in a revisional surgery is proven and medically necessary
    Policy Summary
    PayerUnitedHealthcare
    PolicyBariatric Surgery (for Nebraska Only)
    Policy CodePolicy CS007NE.V
    Change TypeMaterial revisions to coverage criteria and updates to unproven/not medically necessary listCPT code added
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionInclude thorough multidisciplinary documentation and evidence of prior conservative therapies when requesting prior authorization; add CPT 43889 where applicable.
    SourceLink
    On This Page
    Coverage Criteria and Policy PositionsProvider Requirements, Authorization, and DocumentationApplicable Codes and Clinical ThresholdsDefinitions and TerminologyClinical Background and Evidence ContextPolicy Changes and References

    See definitions for conversion/corrective/reversal types

    Unproven / Not medically necessary procedures

    The following procedures/interventions are considered unproven and not medically necessary due to insufficient evidence of efficacy:

    Examples of unproven interventions: Revisional bariatric surgery for indications other than those listed above; Bariatric surgery as the primary treatment for any condition other than obesity; Bariatric artery embolization; Gastric electrical stimulation with an implantable gastric stimulator; Laparoscopic greater curvature plication (total gastric vertical plication); Mini-gastric bypass/one-anastomosis gastric bypass (OAGB/MGB); Silastic ring vertical gastric bypass (SRVGB); Single-anastomosis duodenal switch (SADI/SADS); Transoral endoscopic surgery including endoscopic sleeve gastroplasty (ESG) and transoral outlet reduction (TORe); Vagus nerve blocking (VBLOC); Gastrointestinal liners (e.g., DJBL/EndoBarrier); Intragastric balloons (IGB); TransPyloric Shuttle device

    Listed under Non-State-Specific Criteria as not medically necessary; policy update added SRVGB and TORe and standardized transoral endoscopic entries

    Revisional Surgery Preconditions

    Revisional Surgery — preconditions and considerations

    Pre-revisional assessment: Prior to revisional surgery, individuals should undergo a thorough multidisciplinary assessment including evaluation of anatomical causes versus postoperative behavioral contributors to inadequate weight loss or weight regain; assess risks and benefits; and ensure care is provided in an accredited bariatric program (MBSAQIP) when applicable.

    References Brethauer et al., 2014; MBSAQIP accreditation noted as standard for centers

    Endoscopic/Device Therapy Criteria

    Endoscopic and device-based therapies — intended use and duration

    Intragastric balloon therapy: Intragastric balloons are intended as adjuncts to diet, exercise, and behavioral counseling; available clinical data and manufacturer recommendations indicate a standard duration of therapy of 6 months (insertion to removal).6 months

    Hayes 2021; ASMBS guidance

    TransPyloric Shuttle device: The TransPyloric Shuttle is a nonballoon, space-occupying endoscopic device approved for up to 12 months of therapy in individuals with BMI 35.0–40.0 kg/m2 or BMI 30.0–34.9 kg/m2 with one or more obesity-related comorbid conditions; intended to be used with diet and behavior modification.12 months; BMI 35.0–40.0 or 30.0–34.9 with comorbidity

    FDA PMA April 16, 2019; ECRI 2019

    Revisional Bariatric Surgery — evidence considerations

    Evidence-based considerations for revisional bariatric surgery:

    General considerations: Revisional surgery may be effective for insufficient weight loss or weight regain after primary bariatric procedures; selection of revisional procedure should consider comparative weight-loss efficacy, complication profiles, and patient-specific factors including prior procedure type and comorbidities.

    Supported by multiple systematic reviews and cohort studies

    Procedure-specific tradeoffs: OAGB and SADI/SADS have demonstrated greater EWL/TWL in some analyses but may be associated with higher rates of postoperative GERD or malabsorption; RYGB is commonly used for revision but may have higher early/late complications compared with some alternatives; secondary sleeve gastrectomy may have lower complication rates but inferior weight-loss outcomes in revisional settings.

    See Ataya 2023, Chierici 2022, SADI trial data

    Outcomes and risks: Revisional procedures generally improve metabolic comorbidities (high reported rates of diabetes, hypertension, and OSA improvement) but are associated with higher complication and reoperation rates versus primary procedures; nutritional deficits are a consideration, particularly with distalization or short common channel lengths.

    See Koh 2020, ASMBS guidance, limb-length nutritional risk statements

    Investigational/alternative procedures

    Investigational procedures with limited evidence:

    Bariatric artery embolization: Transcatheter bariatric (left gastric artery) embolization has small, methodologically limited studies including one small sham-controlled RCT showing modest short-term TBWL; long-term safety and efficacy remain uncertain and it is considered investigational.

    Reddy 2020; Hafezi-Nejad 2019; Weiss 2019

    Gastric electrical stimulation: Implantable gastric electrical stimulation devices have mixed early results from small feasibility and cohort studies; high-quality long-term RCT evidence is lacking, so this approach remains investigational for obesity treatment.

    Systematic reviews and small series summarized in policy

    Laparoscopic greater curvature plication (LGCP): LGCP demonstrates variable short-term weight loss with less durable outcomes and higher adverse events compared with standard procedures in some studies; comparative long-term RCT evidence is insufficient, so LGCP is investigational/unproven for durable obesity treatment.

    Multiple cohort studies, RCTs, and meta-analyses cited

    Evidence summaries (no explicit coverage criteria)

    Clinical-evidence summaries and comparative trial findings (no explicit coverage decision language present in these chunks).

    LGCP evidence summary: LGCP yields significant short-term BMI reduction with variable weight regain by 3–5 years; randomized and observational data suggest inferior sustained weight loss and higher adverse events compared with LSG in several studies.

    Dolezalova-Kormanova 2017; Bužga 2017; Grubnik 2016; Tang meta-analysis

    OAGB/MGB evidence summary: OAGB shows comparable or greater short-term weight loss versus RYGB in some trials and meta-analyses but may have higher rates of de novo GERD and marginal ulcers; long-term comparative data remain limited.

    Ahmed 2025 systematic review; Kapellas 2024

    SRVGB evidence summary: Silastic ring vertical gastric bypass may offer modest medium-term weight-loss advantages in limited reports but is associated with device-specific late complications; evidence quality is low.

    Hayes 2025 assessment

    SADI-S/SADS evidence summary: SADI-S demonstrated superior EWL at 2 years versus RYGB in an RCT but has concerns regarding gastrointestinal symptoms, malabsorption, and missing data; observational series report durable EWL but long-term safety and nutritional consequences require monitoring.

    Robert et al.; Esparham 2023 systematic review

    Evidence summaries informing coverage stance

    Coverage considerations based on the presented evidence:

    SADI-S/SADS/SIPS evidence summary: Observational and limited RCT data suggest these single-anastomosis malabsorptive procedures can produce substantial weight loss but raise concerns about nutritional deficiencies and gastrointestinal symptoms; longer-term comparative RCT data are limited.

    Chunks 72-75

    Endoscopic Sleeve Gastroplasty (ESG): ESG provides greater weight loss than lifestyle modification but less weight loss than laparoscopic sleeve gastrectomy; safety signals include low but present SAE rates and increased reinterventions in registry comparisons; long-term comparative evidence is insufficient.

    Chunks 76-84

    Gastrointestinal liner (DJBL/EndoBarrier): DJBL/EndoBarrier improves weight and glycemic measures while implanted but has high early removal (~19%) and SAE (~17%) rates; benefits diminish after explantation and long-term data are heterogeneous.

    Chunks 85-86

    Intragastric balloons (IGB): IGBs produce short-term clinically significant weight loss but weight regain after removal is common; trial evidence shows short-term benefit with mixed long-term durability and increased adverse events in some studies.

    Chunks 87-91

    Coverage considerations tied to trial eligibility and guideline recommendations

    Evidence-supported and guideline-aligned coverage considerations

    Device trial-aligned eligibility: Device therapies (e.g., IGB, VBLOC, dual-balloon systems) should be considered when patient selection matches pivotal trial inclusion criteria (for example, REDUCE included BMI 30–40 kg/m2; ReCharge included BMI 35–45 or 40–45 kg/m2 examples) and when adjunctive supervised diet and behavior programs are provided.see trial BMI ranges

    REDUCE and ReCharge pivotal trials; guideline alignment

    Conservative therapy prior to device/surgery: Patients should have documented failure of conventional multidisciplinary weight-loss strategies (diet, exercise, behavioral modification, and pharmacotherapy when appropriate) before device or surgical interventions are authorized.not numeric

    Per AACE/ASMBS/ADA guidance

    Adult indications for metabolic and bariatric surgery

    Guideline-based indications and age-specific criteria from professional societies

    Adult BMI indications (general): Adults meeting one of the following BMI-based indications: BMI ≥ 40 kg/m2; BMI ≥ 35 kg/m2 with one or more severe obesity-related complications; selected patients with BMI 30–34.9 kg/m2 and inadequately controlled type 2 diabetes or metabolic disease despite optimal medical therapy. Ethnicity-specific lower BMI thresholds may apply (e.g., Asian patients).see BMI thresholds

    ASMBS, AACE, ADA, NICE guidance

    Pediatric/adolescent indications and considerations

    Pediatric and adolescent indications per ASMBS and AAP

    Adolescent indications: MBS may be considered for adolescents >12 years using percentile- and BMI-based thresholds: Class II obesity (e.g., ≥120% of the 95th percentile or BMI ≥35 kg/m2) with clinically significant disease, or Class III obesity (≥140% of the 95th percentile or BMI ≥40 kg/m2); eligibility requires multidisciplinary evaluation, assessment of family stability, and appropriate psychosocial support.percentile-based thresholds as above

    AAP 2023; Endocrine Society guidance

    Procedure and device-specific guidance

    Procedure-specific endorsements and device guidance from ASMBS

    ASMBS endorsements and cautions: ASMBS endorses multiple procedures (sleeve gastrectomy, RYGB, BPD/DS, SADI-S, OAGB, adjustable gastric banding, ESG, IGB) while noting no single procedure suits every patient; endorsement emphasizes need for individualized selection, long-term follow-up, and monitoring for procedure-specific risks.N/A

    ASMBS position statements and endorsements

    Device-specific guidance: IGBs are FDA-approved as temporary tools (maximum 6 months) as adjuncts to supervised diet/behavior programs, require multidisciplinary follow-up and informed consent about AEs; vagal blocking and other devices have limited evidence and require further study before routine use.IGB max 6 months

    ASMBS position statements; FDA labeling

    Revisional bariatric surgery indications, outcomes, and nutritional risk

    Revisional surgery indications and outcomes

    Indications for reoperative bariatric surgery: Reoperative surgery may be considered for persistent obesity, unresolved comorbid disease, complications, intolerable side effects, or inadequate weight loss after primary procedures; selection requires careful multidisciplinary evaluation and consideration of patient anatomy and surgeon experience.N/A

    ASMBS Revision Task Force and literature review

    Outcomes and nutritional risk: Reoperations account for a minority of bariatric operations (~6.3%); conversions and corrective operations have substantial EBWL but carry higher risk; distalization with short common channel (<200 cm) or low total alimentary limb length (TALL <400 cm) increases risk of severe macro- and micronutrient deficiencies and mandates aggressive supplementation and monitoring.CC <200 cm; TALL <400 cm

    Aleassa et al., ASMBS task force

    Guideline-based candidacy and evaluation criteria

    Society guideline-based pediatric/adult bariatric candidacy criteria summarized from referenced guidelines

    Pediatric MBS candidacy (AAP) - age and BMI/comorbidity: AAP recommends MBS for pediatric patients >12 years with Class II obesity (e.g., BMI ≥35 kg/m2 or ≥120% of the 95th percentile) with clinically significant disease, or Class III obesity (BMI ≥40 kg/m2 or ≥140% of the 95th percentile), with multidisciplinary team assessment and referral to experienced centers.age>12; percentile/BMI thresholds as above

    AAP 2023

    Pediatric evaluation considerations: Eligibility should rely on a multicomponent team decision, include assessment of physical and psychosocial factors, confirm family stability, and ensure access to a comprehensive MBS center with long-term follow-up capability; Tanner staging and near-final height guidance apply in some society statements.Tanner 4-5 when indicated

    Endocrine Society and AAP guidance

    Revised Coverage Criteria Notes

    Policy history indicates specific revisions to coverage criteria and lists of unproven/not medically necessary procedures.

    Planned two-stage procedure: Coverage criteria for a planned two-stage procedure were revised; behavioral wording changed to 'adherent to nutrition and exercise'.

    See Policy History/Revision Information

    Unproven/not medically necessary list updates: Added to unproven/not medically necessary: Silastic ring vertical gastric bypass and Transoral endoscopic surgery including transoral outlet reduction (TORe). Removed: stomach aspiration therapy. Terminology standardized for gastrointestinal liners, intragastric balloons, and transoral endoscopic procedures.

    Policy revision effective 2026-08-01

    Unproven and Not Medically Necessary Procedures (updates)

    The policy's list of unproven and not medically necessary procedures was updated; items added and removed as noted.

    Added to unproven/not medically necessary: Silastic ring vertical gastric bypass; Transoral endoscopic surgery including transoral outlet reduction (TORe).

    Explicit additions in policy update

    Removed from unproven/not medically necessary: Stomach aspiration therapy was removed from the list.

    Removal noted in policy history

    Terminology grouping changes: 'Gastrointestinal liners', 'Intragastric balloon', and 'Transoral endoscopic surgery (includes ESG)' were standardized to grouped phrasing such as 'transoral endoscopic surgery including...' to specify liners, IGBs, ESG, and TORe.

    Clarifies grouping of endoscopic procedures

    Bariatric surgery performed as the primary treatment for any condition other than obesity is considered not medically necessary.

    The EndoBarrier (duodenal-jejunal bypass liner) is not approved by the U.S. Food and Drug Administration for use in the United States and is limited by federal law to investigational use only. Available clinical evidence is insufficient to establish long-term safety and effectiveness for routine clinical use.

    Transcatheter bariatric artery embolization and implantable gastric electrical stimulation are considered investigational. Existing studies are small, methodologically limited, and lack sufficient long-term randomized comparative data to characterize efficacy and safety for treatment of obesity.

    Silastic ring vertical gastric bypass (SRVGB) has device-specific complications that may affect candidacy; evidence is limited and heterogeneous, and potential late device-related risks have been described that differ from standard RYGB outcomes.

    Several endoscopic and device-based interventions have insufficient or limited evidence and are listed as unproven, including transoral endoscopic techniques (e.g., endoscopic sleeve gastroplasty, transoral outlet reduction/TORe), certain gastrointestinal liners (e.g., EndoBarrier), and intragastric balloon systems. Additional well‑designed RCTs and longer-term follow-up are needed.

    Coverage for devices or procedures may be excluded when there is a lack of comparative evidence, high loss to follow-up, or insufficient long-term data to demonstrate durable benefit and acceptable safety; in such cases, use outside trial populations or outside research contexts may be considered investigational or not medically necessary.

    Independent of BMI thresholds, current evidence is insufficient to recommend bariatric surgery solely for glycemic control (or solely for lipid lowering or cardiovascular risk reduction); surgery should not be performed for glycemic control alone without meeting established candidacy criteria.

    Bariatric surgery is contraindicated for preadolescent children and should not be performed in pregnant or breastfeeding adolescents or in those planning pregnancy within two years of surgery. Patients must have mastered healthy dietary and activity habits and have no unresolved substance use, untreated eating disorder, or untreated psychiatric illness before MBS is considered.

    Benefit coverage is governed by applicable federal, state, or contractual requirements. Those requirements and laws may mandate coverage or limit services differently than this policy; documentation of medical necessity may be requested but does not guarantee coverage.

    The policy identifies a list of specific procedures and devices considered unproven and not medically necessary, including but not limited to: revisional bariatric surgery for indications other than those enumerated in the policy, bariatric artery embolization, gastric electrical stimulation, laparoscopic greater curvature plication, mini/one‑anastomosis gastric bypass, silastic ring vertical gastric bypass, single‑anastomosis duodenal switch, transoral endoscopic surgery (including ESG and TORe), vagus nerve blocking (VBLOC), gastrointestinal liners, and intragastric balloons.

    The quantity and quality of evidence for many revisional bariatric procedures is generally low to very low, limiting the ability to draw firm conclusions about comparative effectiveness and safety; this uncertainty may inform noncoverage determinations for specific revisional techniques.

    Laparoscopic greater curvature plication (LGCP) is not equivalent to standard bariatric surgeries for durable weight loss. Multiple comparative studies and meta-analyses report inferior sustained weight loss and higher adverse event or revision rates compared with laparoscopic sleeve gastrectomy; LGCP may be considered not medically necessary where durable weight loss is the clinical goal.

    Some studies indicate LGCP yields less sustained weight loss and worse safety outcomes than LSG at follow-up points beyond 12–24 months, supporting concern about inferior long‑term effectiveness and safety in selected series.

    Endoscopic procedures and intragastric balloons have limited long-term data on sustained weight loss and safety; frequent early device removal, loss to follow-up, and regain of weight after explantation are recurring limitations that may affect coverage decisions.

    Early studies of novel devices and techniques often consist of small trials or feasibility studies without comparative or long-term outcome data. Such limited evidence, single-center designs, and short follow-up constrain conclusions about effectiveness and safety.

    NICE interventional guidance has characterized certain procedures (for example, DJBL/EndoBarrier, swallowable gastric balloons, and some single‑anastomosis procedures) as having limited evidence of safety or efficacy and recommends their use primarily within research settings or special arrangements for governance and audit.

    The policy update added silastic ring vertical gastric bypass (SRVGB) and transoral endoscopic surgery including TORe to the list of unproven/not medically necessary procedures; stomach aspiration therapy was removed from the unproven list. SRVGB remains subject to device‑specific complication concerns as described in the evidence base.

    Provider Requirements, Authorization, and Documentation

    Prior Authorization

    Prior authorization required per Nebraska DHHS and COE requirement

    Bariatric procedures for Nebraska members must meet Nebraska DHHS medical necessity criteria (Nebraska Administrative Code § 471-18) and be performed at a Bariatric Surgery Center of Excellence per NAC requirements; prior authorization should reference these state-specific rules when requesting coverage.

    Prior Authorization

    Authorize device-based therapy with documented duration and adjunct program

    Document device-specific treatment duration and adjunctive program participation for endoscopic devices and balloons: the TransPyloric Shuttle is approved for up to 12 months of therapy and intragastric balloons have a standard 6-month placement period; prior authorization should state intended device, planned duration, BMI indication, and that use is adjunctive to diet/behavior programs.

    • TransPyloric Shuttle: 12-month treatment duration and intended for BMI 35.0–40.0 kg/m2 or 30.0–34.9 kg/m2 with comorbidity (used with diet/behavior modification) [[24]]
    • Intragastric balloons (e.g., Orbera): maximum placement period of 6 months and intended as adjunct to long-term supervised diet and behavior modification [[29],[141]]
    Prior Authorization

    Document prior surgery and clinical justification for revisional operations

    For revisional procedures include documentation of the prior bariatric operation and a clear rationale for revision—identify prior procedure type, prior attempts at nonoperative correction (e.g., band manipulation/adjustment), and the specific technical failure or major complication prompting revision.

    • Specify prior procedure (e.g., LAGB, sleeve gastrectomy, RYGB) and timeline.
    • Document attempts to correct problems nonoperatively (records must show manipulation/adjustment attempted for band slippage).
    • State the complication/indication for revision (e.g., erosion, leak, obstruction, staple-line failure, uncontrollable reflux meeting criteria).
    Note

    No explicit prior authorization codes/requirements listed in these excerpts

    The policy excerpts do not list explicit prior authorization CPT codes or step-by-step authorization requirements; providers should follow usual plan prior-authorization processes and include clinical documentation referenced elsewhere in the policy.

    Prior Authorization

    Prior authorization: document prior weight-loss attempts and evidence for novel procedures

    Require documentation of prior conservative weight-loss efforts and a rationale when requesting authorization for novel or less-proven procedures; the policy notes limited long-term data for many newer endoscopic and single-anastomosis procedures and expects demonstration of prior therapy failure.

    • Document prior multidisciplinary conservative therapies (diet, exercise, behavior modification, pharmacologic therapy when appropriate).
    • Explain rationale for selecting investigational/less-proven procedure over standard surgical options.
    Prior Authorization

    Prior authorization: confirm indication and prior conservative treatment

    Confirm the patient meets device- or trial-specific selection criteria and has failed conservative therapy before authorization—pivotal device trials used specific BMI/comorbidity thresholds that should align with the requested indication.

    • Reference trial-consistent BMI/comorbidity eligibility (e.g., REDUCE trial BMI ranges for dual-balloon; ReCharge trial BMI examples for vagal blocking).
    • Include documentation of failure of conservative therapies as required by trial-aligned selection.
    Documentation Required

    Prior authorization: document multidisciplinary care and preoperative assessment

    Document multidisciplinary preoperative care for authorization decisions: include records of dietary therapy, physical activity counseling, behavioral modification, and pharmacologic therapy when applicable, plus a comprehensive preoperative assessment per society guidance.

    • Obesity-focused history and detailed weight history.
    • Evidence of diet, activity, and behavioral interventions with follow-up.
    • Documentation of pharmacologic therapy trials when appropriate.
    Prior Authorization

    Document device FDA indication and program/monitoring plans

    For FDA‑cleared devices and device programs, document device indication, labeled use, and the plan for supervised diet/behavior programs and monitoring; cite FDA labeling where applicable (e.g., Orbera indications) in the authorization request.

    • Confirm device labeling and intended patient BMI range (e.g., Orbera: BMI ≥30 to ≤40; TransPyloric Shuttle: BMI 35.0–40.0 or 30.0–34.9 with comorbidity).
    • Document plan for long-term supervised diet and behavior modification and informed consent about device risks.
    Note

    Prior authorization not specified in this references segment

    No additional prior authorization guidance is provided in the referenced segment; follow plan processes and include the medical-record documentation specified elsewhere in the policy.

    Billing Rule

    Prior authorization/billing note: CPT code 43889 was added

    CPT code 43889 (endoscopic sleeve gastroplasty) was added to the applicable codes list; include this code in authorization and billing requests when ESG (ESG/ESG with OverStitch) is planned.

    • Use CPT 43889 for transoral, endoscopic sleeve gastroplasty when applicable (policy added this code to the applicable list).
    Prior Authorization

    Conservative therapy required prior to surgery

    Authorization for bariatric surgery typically requires documentation that multidisciplinary conservative therapies (dietary therapy, physical activity, behavior modification, and medication management when appropriate) have been attempted and were unsuccessful prior to surgery.

    • Summarize prior nonsurgical interventions and duration in the record.
    • Document adherence or reasons why conservative therapy was insufficient.
    Step Therapy

    Conservative therapy expected first-line

    First-line conservative treatments are expected before considering surgical intervention; authorization should include documentation of dietary therapy, physical activity, behavior modification, and trials of medication management as applicable.

    Documentation Required

    Assess and document non-surgical contributors before revisional surgery

    Before approving revisional surgery, assess and document non‑surgical contributors to failure—evaluate behavioral factors (e.g., eating patterns, adherence), psychiatric comorbidity, and medical causes to ensure revision addresses anatomic rather than behavioral causes.

    • Document assessment of eating/lifestyle behaviors and mental health status.
    • Explain why anatomical revision is appropriate versus further behavioral interventions.
    Note

    Step therapy not specified in these excerpts

    No step therapy (formal sequencing/authorization steps) is specified in these policy excerpts; providers should document prior conservative care but there is no explicit step-therapy program listed here.

    Step Therapy

    Step-therapy/follow-up plan expected for intragastric balloons

    For intragastric balloon authorization consider requiring a documented plan for follow-up and long-term management because weight loss is often transient after removal; include a plan for subsequent behavioral or pharmacologic therapy or consideration of surgery.

    • Document follow-up plan after balloon removal and intended long-term weight-maintenance strategy.
    • Confirm prior failure of conservative strategies before IGB placement.
    Note

    Guidelines: conservative multidisciplinary therapy recommended first

    Professional guidelines recommend multidisciplinary conservative interventions as the initial approach; authorization for surgery or devices should include documentation that these interventions were provided and unsuccessful.

    Documentation Required

    Document multidisciplinary non-surgical therapy prior to surgery

    Document non-surgical therapy trials before surgery: include supervised dietary programs, physical-activity counseling, behavioral modification, and pharmacotherapy when appropriate as part of the preoperative record.

    • List specific programs or clinicians involved and duration of participation.
    • Record response and adherence to these interventions.
    Prior Authorization

    Require documentation of failed conservative therapy prior to IGB

    Specify prior conservative management prior to placement of an intragastric balloon: Orbera and similar FDA‑cleared systems are indicated as adjuncts after failure of conservative strategies and must be used with a supervised diet/behavior program.

    • Document prior supervised diet, exercise, and behavior modification attempts.
    • Confirm patient meets device labeling BMI criteria and understands device time‑limited use (6 months).
    Note

    Step therapy not described in this references segment

    The references segment does not describe a formal step-therapy program; where required, follow the policy's general expectation for documenting prior conservative care and guideline-aligned evaluations.

    Note

    (reserved)

    Reserved.

    Documentation Required

    Medical-record documentation must fully support medical necessity

    Medical records must contain legible documentation supporting medical necessity: include relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures; records must be made available upon request.

    • Include detailed weight history, prior interventions, and objective diagnostic results.
    • Ensure documentation is legible and retained in the medical record for review.
    Documentation Required

    Pre-revisional documentation must show multidisciplinary assessment and anatomic evaluation

    Pre-revisional documentation should reflect a thorough multidisciplinary assessment addressing anatomic causes of inadequate weight loss or weight regain and postoperative behavioral factors before approval for revisional surgery.

    • Document imaging or endoscopic findings that identify anatomical causes.
    • Summarize multidisciplinary team input and rationale for revision.
    Documentation Required

    Include detailed prior-procedure history and reasons for revision

    For revisional cases include required clinical history: prior bariatric procedure type, specific reasons for failure (medical vs behavioral), comorbidities, and prior weight-loss attempts and trajectories to justify the revisional operation.

    • State the index operation, dates, and complications.
    • Provide objective data on weight trajectory and prior management steps.
    Documentation Required

    Document procedural standardization and surgeon training where relevant

    When authorization is for procedures evaluated in randomized trials, documentation should reflect procedural standardization and surgeon training as applicable (trial protocols required standardized laparoscopic procedures performed by trained bariatric surgeons).

    • Indicate surgeon experience and any specialized training relevant to the procedure.
    • Note adherence to standardized procedural steps when relevant to safety/effectiveness.
    Documentation Required

    Document DJBL (EndoBarrier) indication, informed consent, and monitoring plan

    For duodenal-jejunal bypass liners (DJBL / EndoBarrier) authorization and follow-up should document indication, informed consent about device risks, and planned monitoring because studies report notable early removal rates and serious adverse events.

    • Document counseling on device risks (migration, GI hemorrhage, obstruction, hepatic abscess) and plan for AE monitoring.
    • Provide plan for timely device removal and postoperative follow-up.
    Documentation Required

    Document comprehensive preoperative obesity-focused evaluation and testing

    Preoperative evaluation documentation should include an obesity-focused history, detailed weight history, prior weight-loss attempts, and relevant laboratory and diagnostic testing as part of comprehensive assessment for surgical authorization.

    • Include causative factors (medication, family history), prior program participation, and greatest duration of weight loss and maintenance.
    • Document pertinent labs and diagnostics used to assess surgical risk and comorbidities.
    Documentation Required

    Preoperative evaluation: include exam, labs, detailed weight history, and rationale for preop weight loss when applicable

    Expanded preoperative documentation expectations: include physical exam, labs/diagnostics, detailed weight history, and documentation of consideration of preoperative weight loss when it may improve technical aspects of surgery.

    Documentation Required

    Pediatric MBS: document multidisciplinary evaluation and psychosocial assessment

    Pediatric MBS authorization requires multidisciplinary assessment and documentation of psychosocial evaluation, family stability, Tanner stage (when applicable), and near-final adult height per pediatric guidance before approval.

    • Document Tanner stage and near-final height when relevant.
    • Include psychological evaluation confirming family stability and patient adherence ability.
    Note

    References-only segment provides no new documentation obligations

    References do not specify additional documentation requirements beyond those already noted; include cited bibliographic materials only for informational support in the record if relevant.

    Documentation Required

    Medical records may be requested to verify medical necessity

    Medical records supporting authorization may be requested; ensure records fully support medical necessity and include relevant history, examination, and diagnostic test results in legible form.

    Denial Risk

    Denial risk: insufficient medical-record documentation

    Lack of adequate medical-record documentation that supports medical necessity may result in denial of requested services; include all required clinical details to mitigate denial risk.

    • Ensure documentation is legible, complete, and available upon request.
    Denial Risk

    Denial risk for inadequate multidisciplinary assessment before revision

    Failure to document a thorough multidisciplinary assessment and individualized risk–benefit consideration before revisional bariatric surgery could lead to coverage denial.

    • Provide multidisciplinary team notes and rationale addressing anatomical vs behavioral causes of failure.
    Denial Risk

    Denial risk: reoperation/conversion rates require justification

    High rates of reoperation and conversions after some index procedures (notably LAGB) mean prior authorization requests for revision must justify the chosen revisional approach with prior-procedure history and complication data to avoid denials.

    • Document prior procedure outcomes and why conversion or correction is preferred over alternative options.
    Denial Risk

    Denial risk: limited ESG evidence may trigger noncoverage

    Limited evidence for Endoscopic Sleeve Gastroplasty (OverStitch) may lead to noncoverage or additional scrutiny; authorization should include strong supporting documentation when ESG is requested.

    • Include trial evidence, patient selection justification (matching trial populations), and plan for long-term follow-up.
    Denial Risk

    Denial risk: evidence limitations (loss to follow-up, lack of comparative data)

    Cases with inadequate evidence (high loss to follow-up, insufficient comparative data, or lack of long‑term outcomes) may be at risk for denial; supply complete outcome and follow-up data when seeking authorization for devices/procedures with limited evidence.

    • Provide long-term follow-up data if available and rationale for expected benefit despite evidence gaps.
    Denial Risk

    Denial risk: avoid mandatory preoperative weight-loss requirements without justification

    No randomized trial evidence supports mandatory preoperative weight loss; avoid imposing absolute preoperative weight‑loss mandates without clinical justification, as this could risk inappropriate denials inconsistent with guideline statements.

    Denial Risk

    Denial risk: age-based contraindication for adjustable gastric bands

    Adjustable gastric bands are contraindicated in patients under 18 per FDA labeling; prior authorization for band procedures must document age and labeled indications to avoid contraindication-based denial.

    Note

    No additional authorization rules in references-only segment

    This references-only policy segment does not provide additional authorization triggers; rely on the policy's clinical criteria and state/contractual rules for authorization decisions.

    Note

    Coverage governed by federal/state/contract rules; documentation does not guarantee coverage

    Coverage decisions are governed by federal, state, or contractual requirements; failure to provide complete documentation supporting medical necessity may result in denial and documentation does not guarantee coverage.

    Note

    Applicable Codes and Clinical Thresholds

    Applicable CPT codes (partial list)CPT
    0813TEsophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon.
    43290Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon.
    43291Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s).
    43644Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less).
    43645Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption.
    43647Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
    43648Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
    43659Unlisted laparoscopy procedure, stomach.
    43770Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (e.g., gastric band and subcutaneous port components).
    43771Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only.
    1–10 of 11
    1/2
    Applicable CPT codes (continued)CPT
    43773Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of adjustable gastric restrictive device component only.
    43774Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive device and subcutaneous port components.
    43775Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (i.e., sleeve gastrectomy).
    43843Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty.
    43845Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch).
    43846Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy.
    43847Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption.
    43848Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable gastric restrictive device (separate procedure).
    43860Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; without vagotomy.
    43865Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; with vagotomy.
    1–10 of 13
    1/2
    Applicable CPT codes (continued)CPT
    43887Gastric restrictive procedure, open; removal of subcutaneous port component only.
    43888Gastric restrictive procedure, open; removal and replacement of subcutaneous port component only.
    43889Gastric restrictive procedure, transoral, endoscopic sleeve gastroplasty (ESG), including argon plasma coagulation, when performed.
    43999Unlisted procedure, stomach.
    64590Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
    64595Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.
    64999Unlisted procedure, nervous system.
    Applicable CPT Codes (added)CPT
    43889Gastric restrictive procedure, transoral, endoscopic sleeve gastroplasty (ESG), including argon plasma coagulation, when performed.
    Initial BMI for planned two-stage procedure
    Initial BMI threshold≥ 50 kg/m2
    Timing requirementSecond stage must occur within 2 years of the primary bariatric surgery
    Behavioral requirementIndividual has been adherent to nutrition and exercise
    BMI eligibility thresholds reported in trials/guidelines — trial eligibility ranges / examples
    REDUCE trial eligibility exampleBMI 30–40 kg/m2 (dual-balloon DB pivotal trial)
    ReCharge trial eligibility exampleBMI 40–45 kg/m2 or BMI 35–39.9 kg/m2 with at least one obesity-related comorbidity
    Obalon registry indicated use exampleIGB indicated BMI 30–40 kg/m2 in registry analyses
    BMI thresholds — society-specific thresholds for adults and special populations
    Adult general threshold (societies)BMI ≥ 40 kg/m2
    Adult with comorbiditiesBMI ≥ 35 kg/m2 with one or more severe obesity-related complications
    Select patients with metabolic diseaseBMI 30–34.9 kg/m2 (consideration for patients with type 2 diabetes or metabolic disease)
    Asian ethnicity adjustmentBMI ≥ 25 kg/m2 suggests obesity; consider MBS at BMI ≥ 27.5 kg/m2
    Adolescent/pediatric thresholdsClass II: ≥120% of 95th percentile or BMI 35–39.9 kg/m2; Class III: ≥140% of 95th percentile or BMI ≥40 kg/m2

    Definitions and Terminology

    Obesity is defined using body mass index (BMI) and is associated with multiple comorbidities including hypertension, type 2 diabetes, dyslipidemia, cardiovascular disease, obstructive sleep apnea, nonalcoholic fatty liver disease, osteoarthritis, and certain cancers. Professional organizations recommend screening and use of intensive multicomponent behavioral interventions for individuals with BMI ≥ 30 kg/m2 and consider metabolic and bariatric surgery for appropriately selected patients meeting published BMI and comorbidity criteria.

    Body Mass Index (BMI) — definition and adult class ranges
    DefinitionBody Mass Index (BMI) = weight (kg) / height (m)^2
    Adult class IBMI 30.0–34.9 kg/m2
    Adult class IIBMI 35.0–39.9 kg/m2
    Adult class IIIBMI ≥ 40.0 kg/m2
    Underweight / Normal / Overweight<18.5 underweight; 18.5–24.9 normal; 25–29.9 overweight
    Los Angeles Classification of Oesophagitis — LA Grades A–D
    Grade AOne or more mucosal break ≤ 5 mm not extending between tops of two mucosal folds
    Grade BOne or more mucosal break > 5 mm not extending between tops of two mucosal folds
    Grade CMucosal break continuous between tops of two or more mucosal folds but involves <75% of circumference
    Grade DMucosal break involves ≥75% of the esophageal circumference
    Revisional Bariatric Surgery (definitions) — conversion, corrective, restorative
    ConversionA second bariatric procedure that changes the bariatric approach to a different type of procedure (e.g., band to RYGB)
    CorrectiveA procedure that corrects or modifies the anatomy of a previous bariatric procedure to achieve the original desired outcome or correct a complication
    Restorative / ReversalA procedure that restores original anatomy or reverses a prior bariatric operation
    Restrictive vs Malabsorptive Procedures — definition and differences
    Restrictive proceduresLimit stomach capacity to reduce food intake (e.g., sleeve gastrectomy features)
    Malabsorptive proceduresReduce nutrient absorption by altering small bowel continuity (e.g., biliopancreatic diversion, duodenal switch)
    Mixed featuresSome procedures combine restrictive and malabsorptive elements; choice depends on patient-specific factors
    Vertical Sleeve Gastrectomy (VSG) — definition and stomach resection percentage
    DefinitionVertical sleeve gastrectomy (VSG) removes ~60%–75% of the stomach to create a narrow gastric sleeve
    Physiologic effectReduces stomach capacity and decreases ghrelin production to lessen appetite
    Nutrition noteNot purely malabsorptive; lifetime nutritional supplementation is not required routinely
    OAGB — One-anastomosis gastric bypass definition and comparative notes
    DefinitionOne-anastomosis gastric bypass (OAGB/MGB) is a single-anastomosis bariatric bypass (mini-gastric bypass)
    Comparative notesSome analyses report greater early TWL/EWL and higher diabetes remission vs RYGB, but OAGB may have higher rates of de novo GERD and marginal ulcers
    Evidence limitationLong-term data beyond 5 years are limited; additional RCTs needed
    SADI — Single-anastomosis duodeno-ileal bypass definition
    DefinitionSingle-anastomosis duodeno-ileal bypass (SADI) is a single-anastomosis malabsorptive procedure often performed with a sleeve gastrectomy
    Outcomes noteSystematic reviews report high %EWL at long-term follow-up but with risks of malabsorption and need for long-term monitoring
    Trial evidenceRCTs and cohort data show superior short-term EWL vs RYGB in some studies but with notable SAEs and missing data concerns
    LGCP — Laparoscopic greater curvature plication definition
    DefinitionLaparoscopic greater curvature plication (LGCP) reduces gastric volume by folding and suturing the greater curvature without resection
    Effectiveness noteCohort data show BMI reduction with some weight regain by 5 years; comparative studies suggest inferior durable weight loss vs standard bariatric surgeries
    Evidence limitationLack of long-term RCTs and comparative data limits conclusions on durability and safety
    OAGB / MGB — definitions and comparison to RYGB
    DefinitionOAGB/MGB is a single-anastomosis gastric bypass procedure (mini-gastric bypass)
    Comparison to RYGBComparable or greater short-term weight loss in some studies, but higher rates of de novo GERD and marginal ulcers have been reported vs RYGB
    Evidence noteLong-term comparative evidence is limited; interpret advantages/risks cautiously
    SADI-S / SADS — single-anastomosis duodeno-ileal switch definitions
    DefinitionSADI-S / SADS (single-anastomosis duodeno-ileal switch) combines sleeve gastrectomy with a single duodeno-ileal anastomosis to confer malabsorptive effect
    Efficacy noteRCTs and systematic reviews report higher %EWL/TWL vs RYGB in some trials but with concerns about malabsorption and SAEs
    MonitoringLong-term nutritional monitoring and supplementation required due to hypoabsorptive component
    SRVGB — silastic ring vertical gastric bypass definition and concerns
    DefinitionSilastic ring vertical gastric bypass (SRVGB) is RYGB with an implanted silastic ring intended to improve weight-loss maintenance
    ConcernsEvidence limited; device-specific late complications reported and technique heterogeneity limits generalizability
    Evidence statusInsufficient high-quality evidence to establish long-term safety and effectiveness
    SADI-S / SADS / SIPS — related single-anastomosis procedure definitions
    Definitions groupingSADI-S, SADS, and SIPS are related single-anastomosis malabsorptive procedures with similar technical intent
    Comparative noteThese procedures show variable weight-loss and complication profiles compared with BPD/DS and RYGB in cohort studies; long-term RCTs are limited
    Clinical implicationSelection should consider malabsorption risk and need for long-term follow-up
    Endoscopic Sleeve Gastroplasty (ESG) — definition and short-term outcome note
    DefinitionEndoscopic Sleeve Gastroplasty (ESG) is a transoral endoscopic suturing procedure (e.g., OverStitch) that reduces gastric volume
    Outcome noteRCTs and observational studies show short-term weight loss greater than lifestyle modification but less than LSG; long-term data are insufficient
    Evidence limitationComparative trials versus contemporary antiobesity medications and long-term safety/efficacy data are limited
    Duodenal-Jejunal Bypass Liner (DJBL / EndoBarrier) — definition and status
    DefinitionDuodenal-Jejunal Bypass Liner (DJBL / EndoBarrier) is a removable endoluminal liner that bypasses proximal small bowel while implanted
    Safety/statusAssociated with high early removal (~19%) and SAE incidence (~17%); not FDA-approved for routine use in U.S.; investigational status noted
    Effectiveness noteImproves weight and glycemic measures while implanted, but benefits diminish after explantation
    Intragastric Balloon (IGB) — definition and expected short-term effects
    DefinitionIntragastric balloon (IGB) is a temporary space-occupying device placed endoscopically or ingested to induce weight loss
    Duration and effectProduces short-term clinically significant weight loss during implantation; weight regain after removal is common
    Trial examplesREDUCE and other trials enrolled participants typically with BMI 30–40 kg/m2 and showed greater weight loss vs diet/exercise at 24 weeks
    Excess weight loss (EWL) — definition and trial use
    DefinitionExcess weight loss (EWL) = percent reduction of weight above ideal body weight
    Use in trialsCommon coprimary endpoint in device trials (e.g., REDUCE, ReCharge) to assess treatment response
    ReportingOften reported alongside total body weight loss (TWL) in bariatric studies
    Total body weight loss (TWL) — definition and reporting usage
    DefinitionTotal body weight loss (TWL) = percent reduction in total body weight from baseline
    UsageReported in multiple studies and registries for IGBs and surgical outcomes
    Complementary metricUsed with EWL to contextualize clinical effect across populations
    Reoperation (revisional bariatric surgery) — definition and classification
    DefinitionReoperation (revisional bariatric surgery) = any operation after the first bariatric operation that qualified toward center of excellence volume requirements
    SubclassificationIncludes corrective operations (address complications without changing initial operation) and conversions (change index operation to different bariatric operation)
    ContextReoperations composed ~6.3% of bariatric operations in large review; conversions ~30.5% of reoperations
    Corrective operation — definition
    Corrective operation definitionAn operation that corrects or modifies the anatomy of a previous bariatric procedure to achieve the original desired outcome or correct a complication without changing the initial operation
    ExamplesGastric pouch resizing, resleeve gastrectomy, limb length adjustments, device manipulation
    Relation to reoperation statsCorrective operations comprised ~69.5% of reoperations in systematic review
    Conversion — definition distinguishing change of operation type
    Conversion definitionAn operation that changes the index bariatric operation to a different type of bariatric operation (reversal restores original anatomy)
    ExampleAdjustable gastric band converted to Roux-en-Y gastric bypass
    Outcomes noteConversions accounted for ~30.5% of reoperations; mean %EBWL after conversion ~39.3%
    Terminology update — replacement of 'compliant' with 'adherent' in coverage criteria
    Updated terminologyReplaced phrase 'compliant with nutrition and exercise' with 'adherent to nutrition and exercise' in coverage criteria
    Policy impactTerminology change may affect documentation expectations for behavioral adherence prior to staged procedures
    ReferencePolicy History/Revision Information (effective 2026-08-01)

    Clinical Background and Evidence Context

    Obesity is defined by BMI categories and is linked to numerous health conditions that increase morbidity and mortality. Guideline statements from major societies endorse multidisciplinary behavioral, pharmacologic, and surgical strategies for management, with surgery reserved for patients who meet established BMI and comorbidity thresholds and who have documented attempts at conservative therapy.

    The evidence base for many revisional bariatric procedures is limited by small, heterogeneous studies and risk of bias; overall evidence quality is often low or very low, which constrains conclusions about comparative effectiveness and safety.

    A recurrent limitation across endoscopic procedures and intragastric balloon studies is the lack of long-term follow-up and high loss to follow-up, which reduces confidence in durability of benefit and in safety estimates beyond the device treatment period.

    Policy Changes and References

    2026-08-01coverage_criteria_revisionLatest

    Revised coverage criteria for a planned two-stage procedure, including replacing the wording 'compliant with nutrition and exercise' with 'adherent to nutrition and exercise'.

    2026-08-01unproven_list_updateLatest

    Updated list of unproven and not medically necessary procedures: added silastic ring vertical gastric bypass and transoral endoscopic surgery (including transoral outlet reduction/TORe and endoscopic sleeve gastroplasty); removed stomach aspiration therapy; regrouped gastrointestinal liners and intragastric balloons under transoral endoscopic surgery wording.

    The policy cites a comprehensive reference list supporting the evidence summaries and guideline recommendations. These references underpin the policy's assessments and were updated alongside the revisions to coverage language.

    Medical records documentation must be legible and fully support medical necessity; the policy clarifies that requested documentation may be required to determine whether the member meets clinical criteria but does not guarantee coverage. Examples of documentation include relevant medical history, physical examination findings, and results of pertinent diagnostic tests or procedures.